Subscribe

Subscribe to our Newsletter and get informed about new publication regulary and special discounts for subscribers!

IJPPE > Volume 12 > Peroxisome Proliferator-Activated Receptors -...
< Back to Volume

Peroxisome Proliferator-Activated Receptors - Alpha in Chronic Inflammation - Mini-Review

Full Text PDF

Abstract:

The pathogeny of the metabolic syndrome (MetS ) is not fully elucidated, but a link between visceral obesity and the increase of the proinflammatory response was proven. Atherosclerosis, perceived as a metabolic complication, draws attention to the peroxisome proliferator-activated receptors- alpha (PPARα). PPARα receptors are transcription factors involved in lipid metabolism, inflammation and atheromatosis. Hence, it interferes in the pathogeny of cardiovascular diseases and other chronic diseases too (neurological, psychical, neoplasical). The study of the expression of PPARα and its modulation on different level may be beneficial in the treatment of metabolic syndrome, intervening in the modulation of another proinflammatory factors.

Info:

Periodical:
International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 12)
Pages:
1-11
Citation:
E. Popa et al., "Peroxisome Proliferator-Activated Receptors - Alpha in Chronic Inflammation - Mini-Review", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 12, pp. 1-11, 2019
Online since:
February 2019
Export:
Distribution:
References:

[1] A.S. Gami et al., Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death, Journal of the American College of Cardiology. 49(5) (2007) 403-404.

[2] E. Cercosimo, R.A. Defronzo Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases, Diabetes Metab. Res. Rev. 22(6) (2006) 423-436.

DOI: https://doi.org/10.1002/dmrr.634

[3] S. Azhar, Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease, Future Cardiology. 6(5) (2010) 657-691.

DOI: https://doi.org/10.2217/fca.10.86

[4] G. Andries, J.Ch. Fruchart, Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes and Cardiovascular Disease, Journal of American College Cardiology. 48(Suppl9) (2006) 24-32.

DOI: https://doi.org/10.1016/j.jacc.2006.04.097

[5] S. Kersten, B. Desvergne, W. Wahli, Roles of PPARS in health and disease, Nature. 405(6785) (2000) 421–424.

DOI: https://doi.org/10.1038/35013000

[6] A. Yessoufou, W. Wahli, Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels, Swiss Med. Wkl. 140 (2010) w13071.

DOI: https://doi.org/10.4414/smw.2010.13071

[7] S.J. Roberts-Thomson, Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment, Immunology and Cell Biolog. 78(4) (2000) 36-41.

DOI: https://doi.org/10.1046/j.1440-1711.2000.00921.x

[8] D. Yusuf et al., The transcription factor encyclopedia, Genome Biol. 13(3) (2012) 1-30.

[9] J.K. Reddy et al., Chemical carcinogens without mutagenic activity: peroxisome proliferators as a prototype, Toxicol. Pathol. 11(2) (1983) 172–180.

DOI: https://doi.org/10.1177/019262338301100209

[10] C.J. Pol, M. Lieu, K. Drosatos, PPARs: Protectors or Opponents of Myocardial Function?, PPAR Res. 2015 (2015) 835985.

DOI: https://doi.org/10.1155/2015/835985

[11] M.D. Li, X. Yang, A Retrospective on Nuclear Receptor Regulation of Inflammation: Lessons from GR and PPARs. PPAR Res 2011;2011:742785.

DOI: https://doi.org/10.1155/2011/742785

[12] J.P. Vanden Heuvel, J.M. Peters, Peroxisome Proliferators, in: K. Ramos (Ed.), Cellular and Molecular Toxicology (Second Edition), Vol/ 2, New York: Elsevier Science Inc., 2010, pp.145-167.

[13] M. Ricote, A.F. Valledor, C.K. Glass, Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis, Arteriosclerosis, Thrombosis and Vascular Biology. 24(2) (2004) 230–239.

DOI: https://doi.org/10.1161/01.atv.0000103951.67680.b1

[14] E. Popa et al., Flow cytometry analysis of PPAR alpha receptors in metabolic syndrome. Romanian Journal of Laboratory Medicine. 22(4) (2014) 427–438.

[15] A. Zambon et al., Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence, Arterioscler. Thromb. Vasc. Biol. 26(5) (2006) 977-986.

DOI: https://doi.org/10.1161/01.atv.0000204327.96431.9a

[16] J. Youssef, M. Badr, Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control, Journal of Biomedicine and Biotechnology. 2004(3) (2004) 156-166.

DOI: https://doi.org/10.1155/s1110724304308065

[17] I.V. Shirinsky, V.S. Shirinsky Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis, Int. J. Rheumatol. 2011 (2011) 937843.

DOI: https://doi.org/10.1155/2011/937843

[18] M. Rakhshandehroo et al., Peroxisome proliferator-activated receptor alpha target genes, PPAR Res. 2010 (2010) 612089.

DOI: https://doi.org/10.1155/2010/612089

[19] R. Belfort et al., Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome, Journal of Clinical Endocrinology and Metabolism. 95(2) (2010) 829-836.

DOI: https://doi.org/10.1210/jc.2009-1487

[20] D.S. Straus, C.K. Glass, Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms, Trends Immunol. 28(12) (2007) 551-558.

DOI: https://doi.org/10.1016/j.it.2007.09.003

[21] E. Cercosimo, R.A. Defronzo, Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res Rev. 22(6) (2006) 423-436.

DOI: https://doi.org/10.1002/dmrr.634

[22] M.N. Sack et al., Fatty acid oxidation enzyme gene expression is downregulated in the failing heart, Circulation. 94(11) (1996) 2837-2842.

DOI: https://doi.org/10.1161/01.cir.94.11.2837

[23] B. Finck et al., A critical for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation of phenotype by dietary fat content, Proc. Natl. Acad. Sci. 100(3) (2003) 1226-1231.

[24] S. Kersten Regulation of nutrient metabolism and inflammation, Results and Problems in Cell Differentiation. 52 (2010) 13-25.

[25] G.D. Lopaschuk et al., Myocardial fatty acid metabolism in health and disease, Physiological Reviews. 90(1) (2010) 207-258.

[26] C.L. Pol, M. Lieu, K. Drosatos, PPARs: Protectors or Opponents of Myocardial Function?, PPAR Research. 2015 (2015) Article ID 835985.

DOI: https://doi.org/10.1155/2015/835985

[27] S. Ares-Carrasco et al., Proteome changes in the myocardium of experimental chronic diabetes and hypertension: Role of PPARα in the associated hypertrophy, Journal of Proteomics. 75(6) (2012) 1816-1829.

[28] S. Purushothaman, M.M. Sathik, R.R. Nair, Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart, Journal of Cardiovascular Pharmacology. 58(3) (2011) 254-262.

DOI: https://doi.org/10.1097/fjc.0b013e31822368d7

[29] P.M. Barger et al., Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth, J. Clin. Invest. 105(12) (2000) 1723-1730.

DOI: https://doi.org/10.1172/jci9056

[30] P.H. Lou et al., Infarct-remodelled hearts with limited oxidative capacity boost fatty acid oxidation after conditioning against ischaemia/reperfusion injury, Cardiovascular Research. 97(2) (2013) 251–261.

DOI: https://doi.org/10.1093/cvr/cvs323

[31] E.E. Morgan et al., Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure, The American Journal of Physiology—Heart and Circulatory Physiology. 290(5) (2006) H1899–H1904.

DOI: https://doi.org/10.1152/ajpheart.01014.2005

[32] W.S. Lee, J. Kim, Peroxisome, Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions, PPAR Research. 2015 (2015) Article ID 271983.

DOI: https://doi.org/10.1155/2015/271983

[33] B.N. Finck et al., A potential link between muscle peroxisome proliferator-activated receptor-α signaling and obesity-related diabetes, Cell Metabolism. 1(2) (2005) 133-144.

DOI: https://doi.org/10.1016/j.cmet.2005.01.006

[34] D.M. Muoio et al., Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice, Evidence for compensatory regulation by PPARδ, J. Biol. Chem. 277(29) (2002) 26089-26097.

DOI: https://doi.org/10.1074/jbc.m203997200

[35] B.K. Pedersen, M.A. Febbraio, Muscles, exercise and obesity: skeletal muscle as a secretory organ, Nat. Rev. Endocrinol. 8(8) (2012) 457-465.

DOI: https://doi.org/10.1038/nrendo.2012.49

[36] A.G. Holmes et al., Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats, J. Endocrinol. 198(2) (2008) 367-374.

DOI: https://doi.org/10.1677/joe-08-0113

[37] F. Zandbergen, J. Plutzky PPARα in atherosclerosis and inflammation, Biochim Biophys Acta. 1771(8) (2007) 972–982.

[38] C.F. Cheng, H.H. Chen, H. Lin, Role of PPARα and Its Agonist in Renal Diseases, PPAR Resp 2010 (2010) 345098.

[39] S.M. De La Monte, J.R. Wands, Alzheimer's Disease Is Type 3 Diabetes–Evidence Reviewed, J. Diabetes Sci. Technol. 2(6) (2008) 1101-1113.

DOI: https://doi.org/10.1177/193229680800200619

[40] N. Bhat, Linking cardiometabolic disorders to sporadic ad: a perspective on potential mechanisms and mediators, J. Neurochem. 115(3) (2010) 551-562.

DOI: https://doi.org/10.1111/j.1471-4159.2010.06978.x

[41] B. Staels et al., Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism, Circulation. 98(19) (1998) 2088-2093.

DOI: https://doi.org/10.1161/01.cir.98.19.2088

[42] O. Kaidanovich-Beilin, D.S. Cha, R.S. McIntyre, Crosstalk between metabolic and neuropsychiatric disorders, F1000 Biol Reports. 4 (2012) 14..

DOI: https://doi.org/10.3410/b4-14

[43] M.P. Hermans, Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD, Curr. Cardiol. Rev. 6(2) (2010) 112.

DOI: https://doi.org/10.2174/157340310791162686

[44] A.C. Keech et al., Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, The Lancet. 370(9600) (2007) 1687-1697.

DOI: https://doi.org/10.1016/s0140-6736(07)61607-9

[45] J. Lo Verme et al., Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha, J. Pharmacol. Exp. Ther. 319(3) (2006) 1051-1061.

[46] I.C. Van Eekeren et al., Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review, Ther. Adv. Musculoskelet Dis. 5(1) (2013) 33-44.

[47] M. Vacca et al., Clustering nuclear receptors in liver regeneration identifies candidate modulators of hepatocyte proliferation and hepatocarcinoma, PLoS One. 9(8) (2014) e104449.

DOI: https://doi.org/10.1371/journal.pone.0104449

[48] J. Youssef, M. Badr, Peroxisome proliferator-activated receptors and cancer: challenges and opportunities, Br. J. Pharmacol. 164(1) (2011) 68-82.

DOI: https://doi.org/10.1111/j.1476-5381.2011.01383.x

[49] Jo.A. Van Ginderachter, K. Movahedi, J. Van den Bossche, Macrophages, PPARs, and Cancer, PPAR Research. 2008 (2008) 169414..

DOI: https://doi.org/10.1155/2008/169414

[50] J.M. Peters, R.C. Cattley, F.G. Gonzalez, Mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643, Carcinogenesis. 18(11) (1997) 2029-2033.

DOI: https://doi.org/10.1093/carcin/18.11.2029

[51] M.W. Matthiessen et al., Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas, Scand. J. Gastroenterol. 40(2) (2005) 198–205.

DOI: https://doi.org/10.1080/00365520410009573

[52] K.E. Innes et al., Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population, BMC Cancer. 14 (2014) 45..

DOI: https://doi.org/10.1186/1471-2407-14-45

[53] W.W. Lin, M. Karin, A cytokine-mediated link between innate immunity, inflammation, and cancer, J. Clin. Invest. 117(5) (2007) 1175–1183.

DOI: https://doi.org/10.1172/jci31537

[54] T.W. Owens et al., Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy, J. Carcinog. Mutagen. Suppl. 14 (2013) S14-004.

[55] S. Dubrac, M. Schmuth, PPAR-alpha in cutaneous inflammation, Dermatoendocrinol. 3(1) (2011) 23-26.

[56] K. Verstraete et al., Structural basis of the proinflammatory signaling complex mediated by TSLP, Nat. Struct. Mol. Biol. 21(4) (2014) 375-382.

[57] M.Y. Sheu et al., Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models, J. Invest. Dermatol. 118(1) (2002) 94-101.

[58] N.N. Mehta, et al., Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis, J. Transl. Med. 11 (2013) 194..

[59] C.D. Orthez et al., Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate, Eur. J. Pharmacology. 581(1-2) (2008) 177-184.

DOI: https://doi.org/10.1016/j.ejphar.2007.11.040

[60] M.G. Belvisi, J.A. Mitchell, Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease, Br. J. Pharmacol. 158(4) (2009) 994-1003.

DOI: https://doi.org/10.1111/j.1476-5381.2009.00373.x

[61] E.M. Drost et al., Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease, Eur. Resp. Rev. 15(101) (2006) 211-212.

DOI: https://doi.org/10.1183/09059180.00010124
Show More Hide
Cited By:
This article has no citations.